株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

口腔粘膜炎 : パイプライン製品の分析

Oral Mucositis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192750
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
口腔粘膜炎 : パイプライン製品の分析 Oral Mucositis - Pipeline Review, H2 2016
出版日: 2016年08月17日 ページ情報: 英文 90 Pages
概要

口腔粘膜炎は最も一般的な粘膜炎の一種で、がんの外科手術・化学療法・放射線治療の際に併発する衰弱性疾患です。主な症状として、口腔内部の色調異常や唾液分泌減退、粘膜構造の変化、唇・舌での浮腫の発生などがあります。主な治療法としては、口腔洗浄(マウスケア)や、口腔内部の創面切除(デブリードメント)などがあります。

当レポートでは、世界各国での口腔粘膜炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

口腔粘膜炎の概要

治療薬の開発

  • 口腔粘膜炎向けパイプライン製品:概要
  • 口腔粘膜炎向けパイプライン製品:比較分析

各企業で開発中の口腔粘膜炎治療薬

大学/研究機関で研究中の口腔粘膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

口腔粘膜炎治療薬:開発中の製品の一覧(企業別)

口腔粘膜炎治療薬:研究中の製品の一覧(大学/研究機関別)

口腔粘膜炎治療薬の開発に従事している企業

  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • 大塚ホールディングス
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

口腔粘膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

口腔粘膜炎治療薬:開発が休止状態の製品

口腔粘膜炎治療薬:開発が中止された製品

口腔粘膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8372IDB

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2016', provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
  • The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
  • The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oral Mucositis Overview
  • Therapeutics Development
    • Pipeline Products for Oral Mucositis - Overview
    • Pipeline Products for Oral Mucositis - Comparative Analysis
  • Oral Mucositis - Therapeutics under Development by Companies
  • Oral Mucositis - Therapeutics under Investigation by Universities/Institutes
  • Oral Mucositis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Oral Mucositis - Products under Development by Companies
  • Oral Mucositis - Products under Investigation by Universities/Institutes
  • Oral Mucositis - Companies Involved in Therapeutics Development
    • Aldeyra Therapeutics, Inc.
    • Cellceutix Corporation
    • Colby Pharmaceutical Company
    • Daewoong Pharmaceutical Co., Ltd.
    • Galera Therapeutics, Inc.
    • Onxeo SA
    • Oragenics, Inc.
    • Otsuka Holdings Co., Ltd.
    • Soligenix, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Spherium Biomed S.L.
  • Oral Mucositis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AG-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nepidermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rebamipide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-13004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
      • Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
      • Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
      • May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
      • Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
      • Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
      • Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis
      • Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015
      • Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
      • Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis
      • Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015
      • Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting
      • Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Oral Mucositis, H2 2016
  • Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2016
  • Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Onxeo SA, H2 2016
  • Oral Mucositis - Pipeline by Oragenics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Oral Mucositis - Pipeline by Soligenix, Inc., H2 2016
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Oral Mucositis - Pipeline by Spherium Biomed S.L., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Oral Mucositis - Dormant Projects, H2 2016
  • Oral Mucositis - Dormant Projects (Contd..1), H2 2016
  • Oral Mucositis - Dormant Projects (Contd..2), H2 2016
  • Oral Mucositis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Oral Mucositis, H2 2016
  • Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top